{
    "nct_id": "NCT05376878",
    "official_title": "Pilot Study to Evaluate 64Cu-DOTA-Trastuzumab Imaging in Patients With HER2+ Breast Cancer With Brain Metastatsis Treated With Fam-Trastuzumab Deruxtecan",
    "inclusion_criteria": "* Documented informed consent of the participant and/or legally authorized representative\n* Women with documented metastatic HER2 positive breast cancer (American Society of Clinical Oncology [ASCO] College of American Pathologist [CAP] guidelines) who have brain metastases\n* Age > 18 years\n* Eastern Cooperative Oncology Group (ECOG) 0-2\n* Patients with leptomeningeal disease will be considered eligible\n* Planned therapy with fam-trastuzumab deruxtecan\n* Left ventricular ejection fraction (LVEF) > 50%\n* Absolute neutrophil count (ANC) > 1.5 x 10^9/L\n* Platelets > 100 x 10^9/L\n* Hemoglobin > 9 g/dL\n* Total (T.) bilirubin < 3 x upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5 x ULN\n* Creatinine clearance > 30 ml/min (by Cockcroft-Gault formula)\n* Activated partial thromboplastin time (aPTT) < 1.5 x ULN\n* Prior therapy for central nervous system (CNS) disease is allowed, but at least 1 lesion > 1.5 cm is evident on MRI\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Need for immediate local intervention for brain metastases\n* Noninfectious interstitial lung disease or pneumonitis requiring glucocorticoids\n* Clinically significant corneal disease\n* Myocardial infarction < 6 months before, congestive heart failure (CHF), unstable angina, or serious cardiac arrhythmia",
    "miscellaneous_criteria": ""
}